356 related articles for article (PubMed ID: 14614363)
21. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
22. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
Kurz H; Herbich K; Janata O; Sterniste W; Bauer K
J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241
[TBL] [Abstract][Full Text] [Related]
23. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
Lacaze-Masmonteil T; Rozé JC; Fauroux B;
Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
[TBL] [Abstract][Full Text] [Related]
24. Respiratory syncytial virus risk factors in late preterm infants.
Lanari M; Silvestri M; Rossi GA
J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
[TBL] [Abstract][Full Text] [Related]
25. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
26. Prevention of respiratory syncytial virus infection among Puerto Rican infants.
Winchester L; García L; García I; Concepción CB
P R Health Sci J; 2002 Sep; 21(3):191-3. PubMed ID: 12243108
[TBL] [Abstract][Full Text] [Related]
27. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
28. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age.
Park HW; Lee BS; Kim AR; Yoon HS; Kim BI; Song ES; Kim WT; Lim J; Kim S; Jin HS; Byun S; Chee DH; Kim KS
Pediatr Infect Dis J; 2012 Aug; 31(8):e99-104. PubMed ID: 22531234
[TBL] [Abstract][Full Text] [Related]
30. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
32. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
Simoes EA; Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
[TBL] [Abstract][Full Text] [Related]
33. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
Fitzgerald DA
Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada.
Paes B; Cole M; Latchman A; Pinelli J
Curr Med Res Opin; 2009 Sep; 25(9):2191-6. PubMed ID: 19604126
[TBL] [Abstract][Full Text] [Related]
35. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC
J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712
[TBL] [Abstract][Full Text] [Related]
36. Palivizumab use in very premature infants in the neonatal intensive care unit.
Wu SY; Bonaparte J; Pyati S
Pediatrics; 2004 Nov; 114(5):e554-6. PubMed ID: 15520088
[TBL] [Abstract][Full Text] [Related]
37. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.
Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
Acta Paediatr; 2004 Nov; 93(11):1470-3. PubMed ID: 15513574
[TBL] [Abstract][Full Text] [Related]
38. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB;
Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
[TBL] [Abstract][Full Text] [Related]
39. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.
Pediatrics; 1998 Sep; 102(3):531-7. PubMed ID: 9724660
[TBL] [Abstract][Full Text] [Related]
40. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
Grupo de Hospitales Benazuza
An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
